2Waterer G W, Rello J, Wunderink R G. management of communityacquired pneumonia in adults [ J]. Am J Respir Crit Care Med, 2011,183:157 - 164.
3Christ-Crain M, Stoiz D, Bingsser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial[ J]. Am J Respir Crit Care Med,2006,174:84 - 93.
3Ngeow YF,Suwanjutha S,Chantarojanasriri T,et al.An Asian study on the prevalence of atypical respiratory pathogens in community-acquired pneumonia.Int J Infect Dis,2005,9:144-153.
5Ostrosky-Zeichner L,Alexander BD,Kett DH,et al.Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.Clin Infect Dis,2005,41:654-659.
6Food and Drug Administration,HHS.Class Ⅱ Special Controls Guidance Document:serological assays for the detection of betaglucan.Fed Reqist,2004,69:56934-56936.
7Mandell LA,Marrie TJ,Grossman RF,et al.Canadian guidelines for the initial management of community-acquired pneumonia:an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.The Canadian CommunityAcquired Pneumonia Working Group.Clin Infect Dis,2000,31:383-421.
8Woodhead M,Blasi F,Ewig S,et al.Guidelines for the management of adult lower respiratory tract infections.Eur Respir J,2005,26:1138-1180.
9Mandell LA,Bartlett JG,Dowell SF,et al.Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.Clin Infect Dis,2003,37:1405-1433.
10Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low risk patients with community-acquired pneumonia.N Engl J Med,1997,336:243-250.
